Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for September 2010
September 1, 2010
- FDA Launches New Organizational Performance Management System
- Allergan Resolves United States Government Investigation of Past Sales and Marketing Practices Relating to Certain Therapeutic Uses of Botox
- Pfizer to Acquire FoldRx Pharmaceuticals
- Gilead Provides Update on $5 Billion Stock Repurchase Program
- From Oranienburg to the rest of the world: global market launch of Daxas (Roflumilast) kicks off in Germany
- CEO Says Genzyme for Sale
- Novo Nordisk Creates ?App? to Help Doctors Dose Insulin
- FDA MedWatch - Tygacil (tigecycline): Label Change - Increased Mortality Risk
- ZS Pharma To Get $2 Million From Texas
- U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014
- Court Affirms Eli Lilly Patents Protecting Evista
September 2, 2010
- FDA Drug Safety Communication: Increased Risk of Death with Tygacil (tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections
- Orexigen Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave in North America
- SEC Charges Pharmaceutical Company Insider and Former Hedge Fund Manager for Insider Trading, Resulting in Approximately $14 Million in Profits
- K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
- Study Reinforces Long-Known Dangers of Weight-Loss Drug Meridia
September 3, 2010
- Abbott Calls Off Sale of Flu Vaccine Business In Europe
- Merck?s Cladribine Tablets for Multiple Sclerosis Approved in Australia
- CDC: Prescription Drug Use Continues to Increase: U.S. Prescription Drug Data for 2007-2008
- Long term use of oral bisphosphonates may double risk of esophageal cancer
- Pfizer Ends Brain Cancer Drug Deal With Celldex
- Roche Announces Operational Excellence Initiative
- Novartis and Collaborators Discover Novel Antimalarial Drug Candidate
- Cardiome Achieves $30 Million Milestone
September 7, 2010
- A Radical Plan To Save Antibiotics
- UK Drug Regulators Want Avandia Pulled From Market
- Idenix Provides Update on HCV Clinical Development Activities
- BBC Panorama ? 6 September 2010: ?A Risk Worth Taking?? Programme. GlaxoSmithKline Right of Reply Statement
- Momenta Loses Generic Copaxon Bid
- Court Denies Sandoz/Momenta's Summary Judgment of Invalidity in Copaxone Litigation
- Neurogenetic Pharmaceuticals Announces Studies Showing Its Proprietary Compound Reduces Brain Plaques Associated with Alzheimer's Disease
- Plexxikon Data Shows PLX4032 Selectivity Enables Substantial Pathway Inhibition and Significant Clinical Response
September 8, 2010
- Bristol-Myers Squibb to Acquire ZymoGenetics
- Karo Bio Announces That Merck Discontinues Development Of MK-6913 For Hot Flashes
- Drug Company Zogenix Plans Initial Public offering
- Bristol-Myers Squibb To Buy Zymogenetics for $885 Million
- S&P May Pare Credit Ratings On Sanofi-Aventis
- Eli Lilly's Lechleiter Not Interested In Big Acquisitions
- Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010
- Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
September 9, 2010
- Basilea Pharmaceutica AG (CH) - Discontinuation of sale of ceftobiprole in Switzerland
- H. Lundbeck A/S (DK) - Lundbeck wins Federal Trade Commission case in Federal District Court
- Lundbeck wins Federal Trade Commission case in Federal District Court
- Glaxo's Medicine Man
- Johnson & Johnson Giving $200M To Boost Health of Women, Children in Poor Countries
- Ark Announces a Major Business Re-Structuring, a Significant Reduction In Its Fixed Cost Base and the Appointment of a New Chairman
- Personalized medicine market projected to grow 11% annually
- FDA Commissioner Margaret A. Hamburg to Keynote Partnership for Safe Medicines Inaugural Counterfeit Drug Conference
September 10, 2010
- FDA Drug Safety Communication: New Warnings for Using gadolinium-based Contrast Agents in Patients with Kidney Dysfunction
- Bristol-Myers Squibb Begins Tender Offer to Acquire ZymoGenetics, Inc.
- Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria
- Basilea Pharmaceutica AG (CH) - Initiation of first isavuconazole study centers foreseen around year-end
- Nearly 400 Medicines and Vaccines in Development to Fight Infectious Diseases
- Bausch + Lomb Names Daniel M. Wechsler as Global President, Pharmaceuticals
- K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
- FDA Grants Fast Track Status to Tideglusib (Zentylor) for Progressive Supranuclear Palsy
- FDA Won't Disqualify HIV Doctor From Drug Studies
September 13, 2010
- Genzyme Says It Is Preparing to Make Job Cuts
- Forest Responds to FDA Complete Response Letter for Roflumilast
- Genzyme Announces Agreement to Sell Genetic Testing Business to LabCorp
- U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly
- AstraZeneca And UCL Search For Stem Cell cure for blindness
- Genzyme to Lay Off 1,000
- AstraZeneca and UCL Join Forces In Sight-Related Stem Cell Medicine
September 14, 2010
- Merck Launches Mobile App for Diabetes Management
- Icagen Provides Update on ICA-105665
- FDA to Ask Experts to Weigh Restrictions for Diet Pill, Including Withdrawal From Market
- Drug Trial Success Is Just What The Doctor Ordered For Mystic Pharmaceutical Firm's Stock Price
- Anacor Pharmaceuticals Plans IPO
September 15, 2010
- Study: Physicians See Gifts As Payback
- Neurocrine: Depression Drug Ineffective In study
- FDA Extends Review Of Blood Thinner Brilinta
- New Company Offers Conflict-Free Medical Education
- i3 Expands Partnership With Eli Lilly and Company
- Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
September 16, 2010
- FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients
- Glaxo and Genmab Drop IV Version of Immune Drug
- Canon Communications to be Sold to United Business Media
- Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
- Montana Governor Unveils Legislation Aimed at Collecting Taxes Owed to the State from Pharmaceutical Companies
- Montana Gov Says Drug Companies Avoiding Taxes
- Genzyme, Sanofi Execs Face Off Over Takeover
- Swedish Orphan Biovitrum AB (publ) (SE) - Swedish Orphan Biovitrum's distribution agreements with Shire to be discontinued as Shire sets up own Nordic sales organization
- Over 3,400 sites join DEA Nationwide Effort to Take-Back Prescription Drugs On Sept 25
September 17, 2010
- Johnson & Johnson and Crucell in Advanced Negotiations For an All Cash Public Offer of ?24.75 per Ordinary Share of Crucell
- Elan Board Unanimously Accepts McKenna Long Report
- Alkermes Announces FDA Advisory Committee Recommends Approval of Vivitrol for Opioid Dependence
- FDA Accepts Aricept Patch (Donepezil Transdermal System) NDA for Review
- Clinical Study of TT-223 in Combination With a GLP-1 Analogue Does Not Meet Study Efficacy Endpoints
- Johnson & Johnson Plans To Buy Crucell For $2.3B
- Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
September 20, 2010
- FDA Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure
- Actelion Pharmaceuticals Ltd (CH) - Actelion Pharmaceuticals US, Inc. has received subpoena relating to Tracleer
- FDA Reviewing Preliminary Safety Information on Actos (pioglitazone)
- Bad Science: Medical Ghostwriters Who Build a Brand
- Rheumatoid Arthritis Drug Carries Risk Of Potentially Fatal Allergic Reaction
- Bristol-Myers Says Diabetes Drug Meets Study Goal
- US Agency Probes Risks Of Bladder Cancer With Diabetes Pill Actos, Rival To Glaxo's Avandia
- GSK Taps PPD As Key Ally
- FDA Extends Review Of Genentech's Avastin
- Cleveland Biolabs Potential $45 Million Contract
- Novartis Europharm Ltd Withdraws Its Marketing Authorisation Application For Rasival (Aliskiren/Valsartan)
- Genzyme Says Synvisc Approved In Japan
- Novartis, Bausch & Lomb Finish Deal For Eye Drug
- AstraZeneca Urges Increase in FDA Funding
- Compass Healthcare Marketers to Open New West Coast Office
September 21, 2010
- Spiriva As Good As Serevent For Asthma; Glaxo Declines To Donate Drug For Study
- FDA Advisory Committee Unanimously Recommends Approval of Dabigatran Etexilate for Stroke Prevention in Atrial Fibrillation
- Abbott Expects More Than $1B In Solvay Charges
- Reps. Waxman, Dingell, Pallone & Stupak Open Discussion on Potentially Historic Changes in Drug Safety Laws
- 1 In 3 Prescriptions Are Now E-Prescriptions In Massachusetts As Number Of E-Prescribing Physicians Grows to 200,000 Nationwide
- Teva Files New Copaxone Lawsuit Against Mylan
September 22, 2010
- Feds OK Upjohn Site Cleanup
- Novartis Gains US Approval For New MS Drug
- U.S. Steps Into Drug Whistle-Blowers Case
- Glaxo, Theravance Report Relovair Safety Data
- Hoffmann-La Roche Inc. Extends A Potential $62,500 Hand To Help Nearby Stores And Restaurants Stay Afloat
- Bearish Bettors Bombard Biogen Idec Inc. On Rival's FDA Feat
- Top 50 Pharma Companies & Their Pipelines Special Report
- Lundbeck Launches New Research and Development Strategy
- Vical Tumbles On Vascular Drug Study Failure
September 23, 2010
- Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
- Ziopharm Drug Candidate Awarded Orphan Drug Status
- Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in Oncology
- Growth expected in PBM Sector
- AIDS, HIV Patients Getting Help From Pharmaceutical Companies
- European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim
- FDA significantly restricts access to the diabetes drug Avandia
September 24, 2010
- Novartis International AG (CH) - Novartis sells US rights to the overactive bladder treatment Enablex
- Alnylam Provides Update on Novartis Collaboration, Announces Corporate Restructuring, and Reaffirms Financial Guidance for 2010
- Icagen Extends Pfizer Alliance
- Germany's Merck Sees Shares Slide After Setback
- IHS Global Insight Study Shows Slow Growth for European Drug Sales through 2015
- Alnylam Pharma To Cut Up To 30 Pct Of Work Force
- Bristol-Myers Squibb Is Streamlining, Will Cut 840 Jobs Worldwide
September 27, 2010
- Sanofi-Aventis Keeps Genzyme Offer at $69 Per Share
- Actelion Pharmaceuticals Ltd (CH) - CONSCIOUS-2 study with clazosentan does not meet primary endpoint
- Trimeris and Roche Reach Agreement on Trimeris Repayment of Deferred Marketing Expense
- Hospira Receives TGA Approval for Nivestim, Australia's First Biosimilar Filgrastim
- Trimeris Settles Patent Dispute Over Fuzeon
- How Much Is A Life Worth? $93,000 Cancer Drug Pushes Boundaries, And Patients Feel The Pinch
- FDA Approves Oral Contraceptive Beyaz With Folate
- Free Med Ad News Podcast Gives Voice to CME?s Defenders
- Free Med Ad News Podcast Gives Voice to CME?s Defenders
September 28, 2010
- Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
- Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc.
- Pfizer Discontinues Phase 3 Trial of Sutent in Advanced Castration-Resistant Prostate Cancer
- Canon Communications to Present Keynote Address on ?ObamaCare?
- Glaxo Urges FDA To Withdraw Dissolvable Tobacco
- Seattle Genetics Cancer Drug Meets Study Goal
- Pfizer Ends Prostate Cancer Study Of Sutent
- Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company
- $155M In Corporate Housing Planned Near Lilly HQ
- FDA Issues Final Rule on Safety Information During Clinical Trials
- Johnson & Johnson Completes Acquisition of Micrus Endovascular
September 29, 2010
- CPEX Announces Continuation of Strategic Alternatives Review Process
- Rigel Pharma Earns $25M Payment From AstraZeneca
- Why So Shy? What Females of the Facebook Generation Are Not Sharing in the OB/GYN Office that Could Affect Their Health
- GSK Hopes To Bring Work To Its Factory In Zebulon
- 140 Lilly Scientists Have New Base For Designing Cancer Drugs
September 30, 2010
- Bavarian Nordic A/S (DK) - Bavarian Nordic Realigns for Expansion
- Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
- Novartis International AG (CH) - Swiss law expert counters Alcon Independent Director Committee's legal position in proposed merger with Novartis
- MediGene Announces Corporate Restructuring And Aims To Strengthen Pipeline
- Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
- Drugs Before Surgery Help Women Avoid Mastectomies
- Tanezumab Shows Promise For Knee Pain
- Janssen to Assume Caeylx Global Marketing Rights from Merck
- Johnson & Johnson Let Public Down, Chief To Testify
- Chief Justice Sells Pfizer Stock To Take Part In Two High Court Cases
- Baxter Gets Austrian Approval For Flu Vaccine
- Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office
- Teva Provides Update on Status of Neutroval (G-CSF) Biologics License Application Submitted to the U.S. Food and Drug Administration
- BioClinica Responds to Shareholder Letter
